

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended): An oral formulation for gastrointestinal drug delivery which comprises an adhesion site-controlling layer for attaching the formulation to a selected site in the ~~digestive tract~~ intestines, a drug-carrying layer ~~for~~ containing a drug and an adhesive to attach the drug containing layer to the selected site in the intestines when the adhesion site-controlling layer dissolves at the selected site in the intestines, and a protecting layer for protecting the drug in the drug-carrying layer, ~~wherein the drug-carrying layer exists~~ existing between the protecting layer and the adhesion site-controlling layer, ~~and the adhesion site-controlling layer may attach to the protecting layer~~ and the adhesion site-controlling layer is a film made of an enteric polymer.

2. (Original): The oral formulation for gastrointestinal drug delivery according to claim 1 wherein each of the adhesion site-controlling layer, the drug-carrying layer and the protecting layer is in the form of film, and said three layers are laminated.

3. (Currently Amended): The oral formulation for gastrointestinal drug delivery according to claim 2 wherein each of ~~the thickness of~~ the adhesion site-controlling layer, the drug-carrying layer and the protecting layer is have a thickness of from 20 to 100 μm .

4. (Previously Presented): The oral formulation for gastrointestinal drug delivery according to claim 1 wherein the protecting layer is in hemispherical form forming an inner space and an opening part, and the drug-carrying layer exists in the inner space of the protecting layer in

said hemispherical form, and wherein the adhesion site-controlling layer covers the opening part of the protecting layer in said hemispherical form.

5. (Currently Amended): The oral formulation for gastrointestinal drug delivery according to claim 4 wherein ~~the inside depth of the hemisphere is~~ has an inside depth from 50 to 500 μm , ~~the inside diameter of the opening part of the hemisphere is~~ has an inside diameter of from 20 to 800 μm , and each of the ~~thickness of the~~ protecting layer and the adhesion site-controlling layer is has a thickness of from 20 to 100 μm .

6. (Original): The oral formulation for gastrointestinal drug delivery according to claim 1 wherein the drug-carrying layer is a porous sheet substrate soaked with a drug, or a sheet or a film of a gel or a wax which contains a drug.

7. (Original): The oral formulation for gastrointestinal drug delivery according to claim 1 wherein the drug-carrying layer further contains one or more ingredients selected from the group consisting of absorption promoters, protease inhibitors and transporter inhibitors.

8. (Original): The oral formulation for gastrointestinal drug delivery according to claim 1 wherein the protecting layer is a film or a capsule made of a water-insoluble polymer or a wax.

9. (Canceled)

10. (Original): The oral formulation for gastrointestinal drug delivery according to claim 1 wherein the drug is a physiologically active protein or peptide.

11. (Original): The oral formulation for gastrointestinal drug delivery according to claim 1 wherein the drug is G-CSF, interferon or indinavir.

12. (Previously Presented): An oral capsule formulation which is prepared by filling the formulation according to claim 1 in a capsule.

13. (Original): The oral capsule formulation according to claim 12 which is an enteric capsule.

14. (Previously Presented): An oral capsule formulation which is prepared by filling the formulation according to claim 2 in a capsule.

15. (Previously Presented): An oral capsule formulation which is prepared by filling the formulation according to claim 4 in a capsule.

16. (Previously Presented): An oral capsule formulation which is prepared by filling the formulation according to claim 6 in a capsule.

17. (Previously Presented): An oral capsule formulation which is prepared by filling the formulation according to claim 7 in a capsule.

18. (Previously Presented): An oral capsule formulation which is prepared by filling the formulation according to claim 8 in a capsule.

19. (Canceled)

20. (Previously Presented): An oral capsule formulation which is prepared by filling the formulation according to claim 10 in a capsule.

21. (Previously Presented): An oral capsule formulation which is prepared by filling the formulation according to claim 11 in a capsule.

22. (Previously Presented): The oral formulation for gastrointestinal drug delivery according to claim 1 wherein the adhesion site-controlling layer is attached to the protecting layer.

23. (Previously Presented): The oral formulation for gastrointestinal drug delivery according to claim 1 wherein the drug-carrying layer is sealed between the adhesion site-controlling layer and the protecting layer to prevent leaking of the drug.

24. (New): The oral capsule formulation according to claim 14 which is an enteric capsule.
25. (New): The oral capsule formulation according to claim 15 which is an enteric capsule.